At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 450 enrolled
Drug / intervention
Bevacizumab in Combination With Paclitaxel/Carboplatin +1 moredrug
Likely dose
Bevacizumab in Combination With Paclitaxel/Carboplatin 7.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC
In Brief
A Phase 3 clinical trial evaluating Bevacizumab in Combination With Paclitaxel/Carboplatin and IBI305 in Combination with Paclitaxel/Carboplatin for NSCLC. Completed, enrolled 450 participants across 1 site.
Detailed Summary
A randomized, double blind, multicenter phase3 study .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC
CountriesChina
CollaboratorsWuXi CDS Clinical Research (Shanghai) Co.Ltd.
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartNov 2016
Primary CompletionOct 2018
Study CompletionNov 2019
TodayJul 2026
First PostedNov 3, 2016
Enrollment StartNov 28, 2016
Primary CompletionOct 19, 2018
Study CompletionNov 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.7 years ago
Interventions
Bevacizumab in Combination With Paclitaxel/Carboplatindrug
Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
IBI305 in Combination with Paclitaxel/Carboplatindrug
Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg